Hepion Pharmaceuticals, Inc.
HEPA
$0.0642
-$0.0014-2.13%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -32.75% | -52.38% | 1.01% | -20.99% | -40.17% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -84.21% | -75.29% | -83.35% | -58.20% | -39.97% |
| Operating Income | 84.21% | 75.29% | 83.35% | 58.20% | 39.97% |
| Income Before Tax | 73.44% | -4.86% | 86.51% | 53.78% | 72.12% |
| Income Tax Expenses | -- | -- | 100.00% | -- | -- |
| Earnings from Continuing Operations | 73.44% | -113.96% | 86.01% | 53.78% | 72.12% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 73.44% | -113.96% | 86.01% | 53.78% | 72.12% |
| EBIT | 84.21% | 75.29% | 83.35% | 58.20% | 39.97% |
| EBITDA | 84.30% | 75.29% | 83.32% | 58.12% | 39.89% |
| EPS Basic | 99.73% | 92.35% | 91.15% | 73.59% | 81.60% |
| Normalized Basic EPS | 99.84% | 99.40% | 77.05% | 73.58% | 60.63% |
| EPS Diluted | 99.73% | 92.35% | 91.15% | 73.59% | 81.60% |
| Normalized Diluted EPS | 99.84% | 99.40% | 77.05% | 73.58% | 60.63% |
| Average Basic Shares Outstanding | 9,665.60% | 2,694.78% | 58.12% | 75.00% | 51.63% |
| Average Diluted Shares Outstanding | 9,665.60% | 2,694.78% | 58.12% | 75.00% | 51.63% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |